PRISM supports all faculty in recruiting postdocs. The faculty listed on this page have expressed special interest in the PRISM program and most are actively recruiting. As you look for potential postdoc mentors, consider how faculty research interests align with your own.
For an overview of how the Faculty Nomination/Selection process works, please view our Stanford PRISM Faculty Guide.
As a rule of thumb, we recommend starting with the faculty listed on this page and then expanding your search to other faculty across the university. This is not intended to be a comprehensive list of all faculty eligible to appoint postdocs through PRISM.
For School of Medicine faculty, browse SoM Departments or find details about individual faculty members in the School of Medicine via Community Academic Profiles (CAP).
For faculty outside of the School of Medicine, browse departments in the Natural Sciences, Earth Sciences, or Engineering and find details about individual faculty members in these areas via Stanford Profiles.
Please check back often -- Faculty/Lab profiles may be added or edited throughout the application period.
PRISM mentor | Research Interests |
---|---|
Max Diehn Radiation Oncology, Stanford Cancer Center, Stem Cell Bio Regenerative Med
Last Updated: August 28, 2020 |
The overarching research goal of the Diehn lab is to develop and translate novel diagnostic assays and therapies to improve personalized treatment of cancer patients. We have a major focus on the development and application of liquid biopsy technologies for human cancers, with a particular emphasis on lung cancers and circulating tumor DNA (ctDNA). We also investigate mechanisms of treatment resistance to radiotherapy, immunotherapy, and targeted agents. Most of our research projects start by identifying an unmet need in the clinical management of cancer patients that we then try to solve via development or application of novel technologies. We use genomics, bioinformatics, stem cell biology, genome editing, mouse genetics, and preclinical cancer models in our work. Discoveries from our group are currently being tested in multiple clinical trials at Stanford and elsewhere in order to translate them into the clinic.
|
Margaret Fuller Developmental Biology, Genetics, Gynecology and Obstetrics, Stem Cell Bio Regenerative Med
Last Updated: February 27, 2023 |
We study the genetic and molecular mechanisms that regulate proliferation and differentiation in adult stem cell lineages, using the Drosophila male germ line as a model. Our current work is focused on the switch from mitosis to meiosis and how the new gene expression program for cell type specific terminal differentiation is turned on. One emerging surprise is the potential role of alternative processing of nascent mRNAs in setting up the dramatic change in cell state
|
Natalia Gomez-Ospina Ped: Genetics, Stem Cell Bio Regenerative Med
Last Updated: November 16, 2020 |
The main focus of Dr. Gomez-Ospina’s lab is to develop therapies for patients with genetic neurodgenerative diseases. The lab uses genome editing and stem cells to produce definitive treatments for childhood neurodegenerative diseases, many of which are lysosomal storage disorders. Current projects in the lab include developing autologous transplantation of genome-edited hematopoietic stem cells for Mucopolysaccharidosis type I, Gaucher, Krabbe disease, Frontotemporal Dementia, and Friedreich's ataxia. Although there is a strong translational focus to the lab, we are also pursuing basic science questions to understand and enhance our therapies including: 1) increasing the efficiency of genome editing tools, 2) understanding microglia turnover in response to conditioning before hematopoietic stem transplant, and 3) stablishing brain-specific conditioning regimens to neurometabolic diseases. |
Maria Grazia Roncarolo Pediatrics, Med: Bone Marrow Transplant, Stem Cell Bio Regenerative Med
Last Updated: July 13, 2022 |
Roncarolo laboratory is exploring the basic biology and translational applications of human type 1 regulatory cells (Tr1). We are using engineered Tr1, ex vivo Tr1, and alloantigen-specific Tr1 to uncover the molecular frameworks that govern Tr1 identity, differentiation and function. We are also translating Tr1 into the clinic. First, Tr1 can be used as a supportive cell therapy to enhance stem cell engraftment and immune reconstitution after hematopoietic stem cell transplantation (HSCT). Alloantigen-specific Tr1, designed to prevent graft-vs-host disease (GvHD) after allogeneic HSCT, are already being tested in a phase I/II clinical trial (NCT03198234). Second, we are investigating the mechanisms of action and clinical potential of the engineered Tr1 called CD4(IL-10) or LV-10, generated by lentiviral transduction of CD4 T cells with IL10 gene. Besides their immunosuppressive and anti-GvHD properties, LV-10 lyse primary acute myeloid leukemia (AML) cells and delay myeloid leukemia progression in vivo. We are exploring LV-10 as a novel cell immunotherapy for AML. Finally, we are interested in curing inborn errors of immunity by stem cell transplantation or autologous stem cell gene correction. We are testing a gene editing strategy to correct pathogenic mutations in IL10 and IL10 receptor genes, which cause severe and debilitating VEO-IBD (very early onset inflammatory bowel disease) in infants and young children.
|
Ravi Majeti Med: Hematology, Stem Cell Bio Regenerative Med, Stanford Cancer Center
Last Updated: August 16, 2020 |
The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). In parallel, the lab also investigates normal human hematopoiesis and hematopoietic stem cells. Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for both normal and malignant human hematopoietic cells. A major focus of the lab is the investigation of pre-leukemic hematopoietic stem cells in human AML.
|
Aaron Newman Biomedical Data Sciences, Stem Cell Bio Regenerative Med
Last Updated: June 02, 2022 |
Our group combines computational and experimental techniques to study the cellular organization of complex tissues, with a focus on determining the phenotypic diversity and clinical significance of tumor cell subsets. We have a particular interest in developing innovative data science tools that illuminate the cellular hierarchies and stromal elements that underlie tumor initiation, progression, and response to therapy. As part of this focus, we develop new algorithms to resolve cellular states and multicellular communities, tumor developmental hierarchies, and single-cell spatial relationships from genomic profiles of clinical biospecimens. Key results are further explored experimentally, both in our lab and through collaboration, with the goal of translating promising findings into the clinic. As a member of the Department of Biomedical Data Science and the Institute for Stem Cell Biology and Regenerative Medicine, and as an affiliate of graduate programs in Biomedical Informatics, Cancer Biology, and Immunology, we are also interested in the development of impactful biomedical data science tools in areas beyond our immediate research focus, including developmental biology, regenerative medicine, and systems immunology. |
Lucy Erin O'Brien Molecular & Cellular Phys, Stem Cell Bio Regenerative Med
Last Updated: August 31, 2020 |
Mature organs respond to the body's changing needs by moving between different 'states' of cellular flux. What does organ-scale cellular flux look like, and how do these dynamics arise? Our goal is to explain—and ultimately even predict—how large populations of individual cells act to create diverse organ states in response to external change. We believe that the cell dynamics of adult organs can be understood in the granular way that we currently understand embryonic gastrulation. Toward this vision, we build new experimental approaches and conceptual models to decipher how cell life cycles and molecular signaling together create the organ phase space. The fly gut is our testing ground for probing cell dynamics at the organ-scale… …and is a powerful model to study how dynamic cell flux maintains healthy organ form. |
Albert Wu Ophthalmology, Stem Cell Bio Regenerative Med
Last Updated: January 13, 2022 |
Our translational research laboratory endeavors to bring breakthroughs in stem cell biology and tissue engineering to clinical ophthalmology and reconstructive surgery. Over 6 million people worldwide are afflicted with corneal blindness, usually caused by chemical and thermal burns, ocular cicatricial pemphigoid, Stevens-Johnson syndrome, microbial infections, or chronic inflammation. These injuries often result in corneal vascularization, conjunctivalization, scarring, and opacification from limbal epithelial stem cell (LSC) deficiency (LSCD), for which there is currently no durable treatment. The most promising cure for bilateral LSCD is finding an autologous source of limbal epithelial cells for transplantation. Utilizing recent advances in the field of induced pluripotent stem cells (iPSC), our research aims to create a reliable and renewable source of limbal epithelial cells for potential use in treating human eye diseases. These cells will be grown on resorbable biomatrices to generate stable transplantable corneal tissue. These studies will serve as the basis for human clinical trials and make regenerative medicine a reality for those with sight-threatening disease. On a broader level, this experimental approach could serve as a paradigm for the creation of other transplantable tissue for use throughout the body. Stem cell biology has the potential to influence every field of medicine and will revolutionize the way we perform surgery. |
Tom Abel Physics, Kavli Institute
Last Updated: October 18, 2021 |
Tom's current research focuses on studying the formation and evolution of galaxies with new numerical techniques, however, he enjoys all areas of non-linear physics which can be addressed using supercomputer calculations! His research interests span dark matter dynamics, the physics of collisionless shocks, investigating the role that cosmic rays and magnetic fields play in the formation and evolution of galaxies, modeling the formation of stars and black holes as well as turbulence, and applications of numerical general relativity. |
Daniel Akerib Physics, Kavli Institute
Last Updated: July 13, 2022 |
Together with Tom Shutt, Dan works on the LUX and LZ dark matter experiments to search for dark matter in the form of Weakly Interacting Massive Particles, or WIMPs. The detectors use liquid xenon as a target medium in a time projection chamber, or TPC. The Large Underground Xenon (LUX) experiment is currently operating a 250-kg target in the former Homestake gold mine in the Black Hills of South Dakota. Preparations are underway at SLAC to design and build the 7-ton successor, known as LUX-ZEPLIN (LZ). The group is involved in many aspects of data analysis, detector design, xenon purification, control andreadout systems, and detector performance studies. |
Steven Allen Physics, Kavli Institute
Last Updated: July 13, 2022 |
Steve is interested in the physics of the most massive objects in the Universe and how we can use them to probe how the Universe evolved. Steve and his group are currently focused on understanding the astrophysics of galaxies and of galaxy clusters using multi-wavelength observations, and on using large, statistical samples of these objects to probe the natures of dark matter, dark energy and fundamental physics. More information regarding ongoing research and a list of Steve's current group members can be found here. |
Roger Blandford Physics, Kavli Institute
Last Updated: July 13, 2022 |
Roger has broad interests in particle astrophysics and cosmology. Roger and his group are currently working on studies of gravitational lensing, compact objects (black holes, neutron stars and white dwarfs) and cosmic rays, tackling difficult questions such as the unknown nature of the gamma-ray flares of the Crab Nebula. He is interested in topics which range from pure theory through phenomenological studies to analysis of observational data. Some of his groups research is strongly computational but plenty is not. |
Patricia Burchat Physics, Kavli Institute
Last Updated: July 13, 2022 |
Pat and her research group are currently working hard as part of the exciting Large Synoptic Survey Telescope Dark Energy Science Collaboration in the general area of gravitational lensing. Her group is using analytic calculations, simulations and existing astronomical images to thoroughly understand potential systematic biases and challenges in extracting accurate and precise measurements of cosmic shear from gravitational lensing with current and future surveys. Current projects include the study of chromatic effects and blended objects. |
Susan Clark Physics, Kavli Institute
Last Updated: October 18, 2021 |
Susan is broadly interested in astrophysical magnetism and the physics of the interstellar medium (ISM), from diffuse gas to dense, star-forming regions. Susan’s research tackles open questions like the structure of the Milky Way’s magnetic field, the nature of interstellar turbulence, and the role of magnetism in star formation. These big questions demand multiwavelength observations and new data analysis techniques. Susan is particularly interested in deciphering the magnetic ISM using sensitive measurements of synchrotron and polarized dust emission made by cosmic microwave background experiments like the Atacama Cosmology Telescope (ACT) and the Simons Observatory (SO). |
Peter Graham Physics, Kavli Institute
Last Updated: July 13, 2022 |
Peter is broadly interested in theoretical physics beyond the Standard Model, including cosmology, astrophysics, general relativity, and even atomic physics. The Standard Model leaves many questions unanswered including the nature of dark matter and the origins of the fundamental fermion masses, the weak scale, and the cosmological constant. These and other clues such as the unification of the forces are a guide to building new theories beyond the Standard Model. Peter's group are interested in inventing novel experiments to uncover this new physics. |
Chao-Lin Kuo Physics, Kavli Institute
Last Updated: July 13, 2022 |
Chao-Lin’s group use the most ancient light, the Cosmic Microwave Background (CMB) radiation, emitted when the universe was in its infancy to shed light on the question of how the universe began. Currently Chao-Lin's group are involved in a number of experiments such as BICEP/BICEP2/Keck Array and have been working hard on detecting primordial B-mode polarization. His group are involved in both he design and construction of instruments as well as the data analysis and theoretical interpretation. |
Bruce Macintosh Physics, Kavli Institute
Last Updated: July 13, 2022 |
Our group works with adaptive optics - optical systems that correct for aberrations using mirrors that change their shape thousands of times per second. This can allow telescopes located on the Earth to correct for atmospheric turbulence and produce diffraction-limited images, which we use to study giant extrasolar planets through direct imaging with the Gemini Planet Imager (GPI) instrument. Direct imaging of extrasolar planets separates the light of the (faint) planet and (bright) star, allowing us to measure the spectrum of young self-luminous giant exoplanets. We are currently planning an upgrade to GPI, adding a faster adaptive optics system using predictive control, and more accurate wavefront sensors. |
Roger Romani Physics, Kavli Institute
Last Updated: July 13, 2022 |
Roger is interested in a variety of topics in high energy astrophysics and cosmology. Much of Roger's group are currently focused on understanding the cosmic gamma-ray sources discovered by the Fermi Space telescope, principally pulsars and blazars. This inherently multi-wavelength question requires them to use telescopes all over the world and in space in order to assemble data on these objects and then to develop and test theoretical models to explain what we see. |
Aaron Roodman Physics, Kavli Institute
Last Updated: July 13, 2022 |
Aaron's current research focus is the study of dark energy using images from the ongoing Dark Energy Survey (DES) and the future Large Synoptic Survey Telescope (LSST). He is interested in studying dark energy using both galaxy clusters and weak gravitational lensing. His research group connects instrumental work, in particular active optics and wavefront measurements at DES and a program of camera-wide testing at LSST, with cosmology measurements. For example, they are developing a new method to characterize the telescope+camera point spread function using optical data, to be part of the weak lensing data analysis at both DES and LSST. |
Philip Scherrer Physics, Kavli Institute
Last Updated: July 14, 2022 |
Phil's main research interests are in the structure and dynamics of the interior of the sun, how this affect solar activity and through this its effects on terrestrial systems. Phil's group’s primary emphasis is on the structure and dynamics of the solar interior using techniques of helioseismology. His group are interested in both developing instrumentation for solar observatories and in the data analysis of solar magnetic fields from space and from the ground. |
Thomas Shutt Physics, Kavli Institute
Last Updated: July 13, 2022 |
Together with Dan Akerib, Tom works on the LUX and LZ dark matter experiments to search for dark matter in the form of Weakly Interacting Massive Particles, or WIMPs. The detectors use liquid xenon as a target medium in a time projection chamber, or TPC. The Large Underground Xenon (LUX) experiment is currently operating a 250-kg target in the former Homestake gold mine in the Black Hills of South Dakota. Preparations are underway atSLAC to design and build the 7-ton successor, known as LUX-ZEPLIN (LZ). The group is involved in many aspects of data analysis, detector design, xenon purification, control andreadout systems, and detector performance studies. |
Risa Wechsler Physics, Kavli Institute
Last Updated: July 13, 2022 |
How did the Universe form and evolve and what is it made of? Our group works on a range of topics in cosmology and astrophysics, with a focus on the formation of cosmological structure in the Universe, its impact on galaxy formation, and its use in determining the nature of dark matter and dark energy. We build and analyze numerical simulations and develop models of large scale structure and galaxy formation for comparison with large observational datasets, and develop new techniques to learn about the dark side of the Universe from these data. We are actively involved in the ongoing Dark Energy Survey (DES), the Dark Energy Spectroscopic Instrument (DESI) and the Large Synoptic Survey Telescope (LSST), and also work on finding, measuring, and modeling dwarf galaxies with the SAGA survey. |
Maria Grazia Roncarolo Pediatrics, Med: Bone Marrow Transplant, Stem Cell Bio Regenerative Med
Last Updated: July 13, 2022 |
Roncarolo laboratory is exploring the basic biology and translational applications of human type 1 regulatory cells (Tr1). We are using engineered Tr1, ex vivo Tr1, and alloantigen-specific Tr1 to uncover the molecular frameworks that govern Tr1 identity, differentiation and function. We are also translating Tr1 into the clinic. First, Tr1 can be used as a supportive cell therapy to enhance stem cell engraftment and immune reconstitution after hematopoietic stem cell transplantation (HSCT). Alloantigen-specific Tr1, designed to prevent graft-vs-host disease (GvHD) after allogeneic HSCT, are already being tested in a phase I/II clinical trial (NCT03198234). Second, we are investigating the mechanisms of action and clinical potential of the engineered Tr1 called CD4(IL-10) or LV-10, generated by lentiviral transduction of CD4 T cells with IL10 gene. Besides their immunosuppressive and anti-GvHD properties, LV-10 lyse primary acute myeloid leukemia (AML) cells and delay myeloid leukemia progression in vivo. We are exploring LV-10 as a novel cell immunotherapy for AML. Finally, we are interested in curing inborn errors of immunity by stem cell transplantation or autologous stem cell gene correction. We are testing a gene editing strategy to correct pathogenic mutations in IL10 and IL10 receptor genes, which cause severe and debilitating VEO-IBD (very early onset inflammatory bowel disease) in infants and young children.
|
Everett Meyer Med: Bone Marrow Transplant, Stanford Cancer Center
Last Updated: August 13, 2020 |
|
Melody Smith Med: Bone Marrow Transplant
Last Updated: November 10, 2021 |
Our lab focuses on the biology of chimeric antigen receptor (CAR) T cells in order to improve the efficacy and safety of this therapy (1) by investigating donor and third-party CAR T cells in an immunocompetent mouse model of allogeneic hematopoietic cell transplant (allo-HCT) and (2) by assessing the impact of the intestinal microbiome on CAR T cell response. We will seek to enhance the development, administration, and mechanistic understanding of how to safely administer donor and third-party CAR T cells with the aim to potentially translate our work to the clinic. We will investigate the regulatory mechanism of the impact of bacterial taxa and the metabolites that they produce on CAR T cell outcomes.
|
Justin Annes Med: Endocrin, Geronot & Metab
Last Updated: July 13, 2022 |
My lab works towards developing novel therapeutics for Diabetes and Endocrine Cell Tumors. To achieve this goal, we develop (1) new animal disease models to better understand disease pathogenesis (biologists), (2) innovative screening/discovery platforms to identify potential therapeutic targets and lead compounds (biologists/biochemists) and (3) synthesize new chemical entities with desired activities for therapeutic application (medicinal chemists). Hence, typical projects in the lab are interdisciplinary and collaborative where the work of biologists is supported by the power of synthetic chemistry . A major current theme in the lab is addressing the challenge of cell-targeted drug delivery, i.e. how can we develop a medicine that only acts on the cell type of interest and apply this to (a) a regenerative therapy for diabetes and (b) the treatment of cancer. If you're excited about disease modeling and/or drug discovery (in diabetes and cancer) my lab might be a good match for you. |
Joy Wu Med: Endocrin, Geronot & Metab
Last Updated: November 29, 2021 |
As a physician scientist with a clinical focus on osteoporosis, my laboratory focuses on stem cell sources for bone-forming osteoblasts, and osteoblast support of hematopoiesis in the bone marrow. In particular we are interested in the pathways that promote osteoblast differentiation, using genetically modified mice and lineage tracing techniques in vivo. We are also studying the role of the osteoblast niche in normal hematopoiesis and bone metastases from breast cancer.
|
Justin Annes Med: General Internal Medicine
Last Updated: February 06, 2023 |
Diabetes is a disorder of glucose homeostasis that causes excess hospitalization, morbidity and early mortality among the more than 34.2 million disease-affected Americans. Consequently, developing pharmacologic methods to preserve β-cell function and/or stimulate β-cell mass expansion is of intense interest. Presently, the creation of improved diabetes medications is stymied by a dearth of safe therapeutic targets. In fact, on-target but off-tissue drug effects are slowing progress across multiple diabetes therapeutic domains including β-cell regeneration, β-cell preservation, and immune-protection. In principle, stimulating the regeneration of insulin-producing β-cells could be used to restore or enhance endogenous insulin production capacity. Recently, we developed several new highly potent chemical inducers of human β-cell proliferation. However, the non-selective growth-promoting activity of these molecules prevents further clinical development. Consequently, a “modular” (readily transferable) system for β-cell-targeted drug delivery is needed to realize the next generation of diabetes therapeutics. To address this challenge, we are developing a β-cell-targeted drug delivery module based upon the uniquely high zinc content of β-cells. In this system, a zinc-chelating moiety is covalently integrated into a replication-promoting (cargo) compound to generate a bi-functional compound (βRepZnC) that selectively enhances β-cell drug accumulation and replication-promoting activity (PMID: 30527998). We are seeking a motivated post-doctoral scholar to join our collaborative research team. This scientist will lead and engage in developing novel βRepZnCs and uncover the biology of β-cell failure. They will define the chemical “rules” that govern zinc-dependent β-cell drug targeting, examine the in vivo β-cell selectivity (accumulation and replication-promoting activity) of newly developed βRepZnCs (work is supported by a synthtic chemist) and use CRISPR technology to genetically dissect the pathways that control β-cell zinc and zinc-binding drug accumulation. These studies will a break-through technology for β-cell-targeted drug delivery and provide fundamental (targetable) insights into β-cell biology. This work has the potential to transform our therapeutic approach to diabetes and provide critical insights into β-cell biology.
|
Josh Knowles Med: Cardiovascular Medicine, Cardiovascular Med Institute, Med: Prevention Research Cntr
Last Updated: January 13, 2022 |
The overall theme of our research has been the genetic basis of cardiovascular disease across the continuum from Discovery to the development of Model Systems to the Translation of these findings to the clinic and most recently to the Public Health aspect of genetics. Currently our Discovery and basic translational efforts center on understanding the genetic basis of insulin resistance using genome wide association studies coupled advanced genetic analyses such as colocalization with exploration using in vitro and in vivo model systems including induced pluripotent stem cells and and gene editing screens.
|
Thomas Robinson Ped: General Pediatrics, Med: Prevention Research Cntr, Epidemiology and Population Health, Cardiovascular Med Institute, Stanford Cancer Center, Woods Institute, HumanCentered Artificial Inte
Last Updated: January 27, 2023 |
Stanford Solutions Science Lab. The Stanford Solutions Science Lab designs solutions to improve health and well-being of children, families, and the planet. Dr. Robinson originated the solution-oriented research paradigm. He is known for his pioneering obesity prevention and treatment research, including the concept of stealth interventions. His research applies social cognitive models of behavior change to behavioral, social, environmental and policy interventions for children and families in real world settings, making the results relevant for informing clinical and public health practice and policy. His research is largely experimental, conducting rigorous school-, family- and community-based randomized controlled trials. He studies obesity and disordered eating, nutrition, physical activity/inactivity and sedentary behavior, the effects of television and other screen time, adolescent smoking, aggressive behavior, consumerism, and behaviors to promote environmental sustainability. Rich longitudinal datasets of physical, physiological, psychological, behavioral, social, behavioral, and multi-omics measures are available from our many community-based obesity prevention and treatment trials in low-income and racial/ethnic minority populations of children and adolescents and their parents. Stanford Screenomics Lab - Human Screenome Project. People increasingly live their lives through smartphones. Our Stanford Screenomics app captures everything that people see and do on their smartphone screens – a record of digital life – by taking a screenshot every 5 seconds. The resulting sequence of screenshots, make up an individual’s screenome, an unique and dynamic sequence of exposures, thoughts, feelings, and actions. To date, we have collected more than 350 million screenshots from 6-12 months of phone use from national samples of about 500 hundred adults and adolescents and their parents. Opportunities available to study the screenome to understand digital media use and its impacts on health and behavior, develop novel diagnostics and prognostics from the screenome, and deliver precision interventions to improve health and well being. An opportunity to help build this paradigm-disrupting new science. |
SUZAN CARMICHAEL Pediatrics, Maternal Fetal Medicine and Obstetrics, Epidemiology and Population Health
Last Updated: January 29, 2023 |
Our team is committed to finding ways to improve maternal and infant health outcomes and equity by leading research that identifies effective leverage points for change, from upstream 'macro' social and structural factors, to downstream 'micro' clinical factors through a collaborative research approach that integrates epidemiologic approaches with community engagement and systems thinking. Disparities are prominent in maternal and infant health, so a lot of our work is centered on equity. Focusing on highest-risk groups will improve health for everyone. Much of our current research focuses on severe maternal morbidity (SMM). SMM encompasses adverse conditions that put pregnant people at risk of short and long-term consequences related to labor and delivery, including death. We also study other important perinatal outcomes, including stillbirth, preterm birth, structural congenital malformations and other maternal morbidities. We are interested in these outcomes individually, as well as in how they are connected to each other -- from a mechanistic standpoint (ie, do they share the same causes), and a lifecourse perspective (eg, how does an adverse newborn outcome affect the mom's postpartum health, and vice versa). Dr. Carmichael's training is in perinatal and nutritional epidemiology. She deeply appreciates her multi-disciplinary colleagues who make this work more meaningful by bringing their own varied perspectives and lived experiences, and their expertise in clinical care, qualitative and mixed methods, community engagement, and state-of-the-art epidemiologic approaches and biostatistical methods. |
Suzan Carmichael Pediatrics, Maternal Fetal Medicine and Obstetrics
Last Updated: July 13, 2022 |
Dr. Carmichael is a perinatal and nutritional epidemiologist and Professor of Pediatrics and Obstetrics and Gynecology at the Stanford University School of Medicine. Her research focuses on finding ways to improve maternal and infant health. Exposure themes include nutrition, social context, care, environmental contaminants and genetics. Outcome themes include severe maternal morbidity, stillbirth, birth defects, and preterm delivery. She is particularly interested in understanding the intersectionality of these varied types of exposures and outcomes and how they interact to impact health and health disparities, for the mother-baby dyad, in domestic as well as global health settings. She currently (mid 2020) has an opening in her lab for a post-doc focused on maternal health. |
Virginia Winn Maternal Fetal Medicine and Obstetrics, Reproductive Biology
Last Updated: January 27, 2023 |
Her lab seeks to understand the unique biological mechanisms of human placentation. While the placenta itself is one of the key characteristics for defining mammals, the human placenta is different from most available animal models: it is one of the most invasive placentas, and results in the formation of an organ comprised of cells from both the fetus and the mother. In addition to this fascinating chimerism, fetal cells are deeply involved in the remodeling of the maternal vasculature in order to redirect large volumes of maternal blood to the placenta to support the developing fetus. As such, the investigation of this human organ covers a large array of biological processes, and deals not only with understanding its endocrine function, but the physiologic process of immune tolerance, vascular remodeling, and cellular invasion. As a physician scientist, Dr. Winn’s ultimate goal is to see this knowledge translate to improved clinical care resulting in healthier mothers and babies. Her lab uses a combination of molecular, cellular, tissue and translational studies in their research. |
Kelly Gaffney PULSE Institute
Last Updated: July 13, 2022 |
Professor Gaffney leads a research team focused on femtosecond resolution measurements of chemical dynamics in complex condensed phase systems. This research takes advantage of recent advances in ultrafast x-ray lasers, like the LCLS at SLAC National Accelerator Laboratory, to directly observe chemical reactions on the natural time and length scales of the chemical bond – femtoseconds and Ångströms. This research focuses on the discovery of design principles for controlling the non-equilibrium dynamics of electronic excited states and using these principles to spark new approaches to light-driven catalysis in chemical synthesis. This research builds on Professor Gaffney’s extensive experience with ultrafast optical laser science and technology. This work began with time- and angle- resolved two photon photoemission studies of electron solvation and localization at interfaces as a graduate student working with Professor Charles Harris at the University of California at Berkeley and extended to multidimensional vibrational spectroscopy studies of hydrogen bonding and ion solvation dynamics in solution during postdoctoral studies with Professor Michael Fayer at Stanford and as an Assistant Professor. The transition to ultrafast x-ray science began in 2004 at SLAC, where he helped establish the first chemical dynamics research program at SLAC. |
Utkan Demirci Stanford Cancer Center
Last Updated: June 29, 2022 |
Utkan Demirci is a professor at Stanford University School of Medicine and serves as the interim division chief and co-director of the Canary Center for Cancer Early Detection in the Department of Radiology. His group focuses on developing innovative microfluidic biomedical technology platforms with broad applications to multiple diseases. Some of his inventions have already been translated into Food and Drug Administration-approved products serving patients. He has mentored and trained many successful scientists, entrepreneurs, and academicians. Currently, the group has a strong core focused on bio fabrication, Extracellular vesicle enrichment, and isolation, small-scale robotics for biomedicine, and the development of point-of-care metamaterial-based optical sensors. |
Max Diehn Radiation Oncology, Stanford Cancer Center, Stem Cell Bio Regenerative Med
Last Updated: August 28, 2020 |
The overarching research goal of the Diehn lab is to develop and translate novel diagnostic assays and therapies to improve personalized treatment of cancer patients. We have a major focus on the development and application of liquid biopsy technologies for human cancers, with a particular emphasis on lung cancers and circulating tumor DNA (ctDNA). We also investigate mechanisms of treatment resistance to radiotherapy, immunotherapy, and targeted agents. Most of our research projects start by identifying an unmet need in the clinical management of cancer patients that we then try to solve via development or application of novel technologies. We use genomics, bioinformatics, stem cell biology, genome editing, mouse genetics, and preclinical cancer models in our work. Discoveries from our group are currently being tested in multiple clinical trials at Stanford and elsewhere in order to translate them into the clinic.
|
Andrew Gentles Biomedical Data Sciences, Biomedical Informatics, Stanford Cancer Center, Neuroscience Institute
Last Updated: January 12, 2022 |
Our research focus is in computational systems biology, primarily in cancer and more recently in neurodegenerative diseases. We develop and apply methods to understand biological processes underlying disease, using high-throughput genomic and proteomic datasets and integrating them with phenotypes and clinical outcomes. A key interest is dissecting how the cellular composition and organization of tissues affects their behaviour in disease; and how these things might be targeted for therapy or diagnostic purposes. We collaborate with many wet lab and clinical groups at Stanford, including in the areas of cancer, immunology, and neuroscience. |
Craig Levin Radiology, Physics, Electrical Engineering, Bioengineering, Radiology-MIPS, Stanford Cancer Center, Cardiovascular Med Institute, Neuroscience Institute
Last Updated: March 16, 2022 |
The research interests of the molecular imaging instrumentation lab are to create novel instrumentation and software algorithms for in vivo imaging of molecular signatures of disease in humans and small laboratory animals. These new cameras efficiently image radiation emissions in the form of positrons, annihilation photons, gamma rays, and/or light emitted from molecular contrast agents that were introduced into the body and distributed in the subject tissues. These contrast agents are designed to target molecular pathways of disease biology and enable imaging of these biological signatures in tissues residing deep within the body using measurements made from outside the body. The goals of the instrumentation projects are to advance the sensitivity and spatial, spectral, and/or temporal resolutions, and to create new camera geometries for special biomedical applications. The computational modeling and algorithm goals are to understand the physical system comprising the subject tissues, radiation transport, and imaging system, and to provide the best available image quality and quantitative accuracy. The work involves designing and building instrumentation, including arrays of position sensitive sensors, readout electronics, and data acquisition electronics, signal processing research, including creation of computer models, and image reconstruction, image processing, and data/image analysis algorithms, and incorporating these innovations into practical imaging devices. The ultimate goal is to introduce these new imaging tools into studies of molecular mechanisms and treatments of disease within living subjects.
|
Ravi Majeti Med: Hematology, Stem Cell Bio Regenerative Med, Stanford Cancer Center
Last Updated: August 16, 2020 |
The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). In parallel, the lab also investigates normal human hematopoiesis and hematopoietic stem cells. Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for both normal and malignant human hematopoietic cells. A major focus of the lab is the investigation of pre-leukemic hematopoietic stem cells in human AML.
|
Everett Meyer Med: Bone Marrow Transplant, Stanford Cancer Center
Last Updated: August 13, 2020 |
|
Thomas Robinson Ped: General Pediatrics, Med: Prevention Research Cntr, Epidemiology and Population Health, Cardiovascular Med Institute, Stanford Cancer Center, Woods Institute, HumanCentered Artificial Inte
Last Updated: January 27, 2023 |
Stanford Solutions Science Lab. The Stanford Solutions Science Lab designs solutions to improve health and well-being of children, families, and the planet. Dr. Robinson originated the solution-oriented research paradigm. He is known for his pioneering obesity prevention and treatment research, including the concept of stealth interventions. His research applies social cognitive models of behavior change to behavioral, social, environmental and policy interventions for children and families in real world settings, making the results relevant for informing clinical and public health practice and policy. His research is largely experimental, conducting rigorous school-, family- and community-based randomized controlled trials. He studies obesity and disordered eating, nutrition, physical activity/inactivity and sedentary behavior, the effects of television and other screen time, adolescent smoking, aggressive behavior, consumerism, and behaviors to promote environmental sustainability. Rich longitudinal datasets of physical, physiological, psychological, behavioral, social, behavioral, and multi-omics measures are available from our many community-based obesity prevention and treatment trials in low-income and racial/ethnic minority populations of children and adolescents and their parents. Stanford Screenomics Lab - Human Screenome Project. People increasingly live their lives through smartphones. Our Stanford Screenomics app captures everything that people see and do on their smartphone screens – a record of digital life – by taking a screenshot every 5 seconds. The resulting sequence of screenshots, make up an individual’s screenome, an unique and dynamic sequence of exposures, thoughts, feelings, and actions. To date, we have collected more than 350 million screenshots from 6-12 months of phone use from national samples of about 500 hundred adults and adolescents and their parents. Opportunities available to study the screenome to understand digital media use and its impacts on health and behavior, develop novel diagnostics and prognostics from the screenome, and deliver precision interventions to improve health and well being. An opportunity to help build this paradigm-disrupting new science. |
Michal Bajdich SLAC National Accelerator Lab, SUNCAT Center for Interface Science and Catalysis, Energy Science Engineering
Last Updated: January 27, 2023 |
|
Michael Ftoney SLAC National Accelerator Lab
Last Updated: July 13, 2022 |
Our research is focused on structural characterization of materials used for energy conversion and storage and for desalination. We use X-ray techniques at SSRL to establish structure-function relationships in complex materials. |
Siegfried Glenzer SLAC National Accelerator Lab
Last Updated: July 13, 2022 |
X-ray laser physics; matter at extreme conditions and fusion research
|
Johanna Nelson Weker SLAC National Accelerator Lab
Last Updated: August 11, 2020 |
The Weker Research Group is at the Stanford Synchrotron Radiation Lightsource (SSRL), a Directorate of the SLAC National Accelerator Laboratory. SLAC is a Department of Energy National Lab managed by Stanford Univeristy. Our research is focused on X-ray microscopy and X-ray characterization of materials far from equilibrium. Using X-rays we study a broad range of systems including energy storage materials such as Li-ion batteries, catalysts, and 3D metal printing (additive manufacturing). |
Ritimukta Sarangi Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Lab
Last Updated: September 29, 2020 |
Dr. Sarangi is a senior scientist at Stanford Synchrotron Radiation Lightsource (SSRL) at SLAC National Accelerator Laboratory with 19 years of experience in the application of a combination of hard and soft x-ray spectroscopic techniques to a range of systems, from complex biological/biomimetic catalysts to related homogenous catalyst systems. One of her main research foci is understanding the mechanism of first row transition metal metalloenzyme active sites involved in redox catalysis. She drives the technological development on several x-ray spectroscopy facilities and plays a critical role in training and dissemination of synchrotron-based techniques. She is also involved in strategic planning to enhance access of various research user communities to SSRL facilities. |
Kazuhiro Terao SLAC National Accelerator Lab
Last Updated: January 12, 2022 |
Our group at SLAC National Accelerator Laboratory is leading R&D of machine learning applications for in the area of experimental neutrino physics and a wider community of High Energy Physics. Modern neutrino experiments employ a big (100 to 10,000 tonnes), high-resolution (~mm/pixel) particle imaging detectors that records meters-long particle trajectories produced from a neutrino interaction. We address fundamental challenges in modeling these detectors, analyzing particle images, and inferring physics from big data using machine learning and advanced computing techniques. Our research has potential to accelerate physics discovery process by orders of magnitude and to maximize physics information extracted from the big, high-recision particle imaging detectors. Areas of technical R&D include:
Areas of physics research include:
For details, feel free to contact Kazuhiro Terao. |
Thomas Wolf SLAC National Accelerator Lab
Last Updated: February 24, 2023 |
The Wolf Research Group investigates ultrafast photochemical dynamics in isolated molecules. We are part of the Stanford PULSE Institute, a Stanford independent laboratory and a research center at SLAC National Accelerator Laboratory. Our offices and lab space are on the SLAC campus. For our research, we use SLAC’s large-scale research facilities, such as the Linac Coherent Light Source (LCLS), the world’s first hard X-ray free electron laser, and the megaelectronvolt ultrafast electron diffraction (MeV-UED) facility within LCLS. |
Ritimukta Sarangi Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Lab
Last Updated: September 29, 2020 |
Dr. Sarangi is a senior scientist at Stanford Synchrotron Radiation Lightsource (SSRL) at SLAC National Accelerator Laboratory with 19 years of experience in the application of a combination of hard and soft x-ray spectroscopic techniques to a range of systems, from complex biological/biomimetic catalysts to related homogenous catalyst systems. One of her main research foci is understanding the mechanism of first row transition metal metalloenzyme active sites involved in redox catalysis. She drives the technological development on several x-ray spectroscopy facilities and plays a critical role in training and dissemination of synchrotron-based techniques. She is also involved in strategic planning to enhance access of various research user communities to SSRL facilities. |
Pascal Geldsetzer Med: Primary Care and Population Health, Epidemiology and Population Health
Last Updated: December 01, 2021 |
We are a highly interdisciplinary group with a diverse set of research interests that span various areas of medicine and public health. These interests include i) the use of novel causal inference techniques in electronic health record data to assess the real-life effectiveness of clinical (e.g., medications), behavioral, and health services interventions; ii) deep learning in satellite imagery and other publicly available geotagged data sources to monitor health indicators in low- and middle-income countries; iii) the re-analysis of clinical trial data to gain novel insights; and iv) randomized trials and analysis of household surveys in low- and middle-income countries to improve population health (with a focus on chronic conditions, particularly cardiovascular disease risk factors). |